# A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

> **NCT05686759** · PHASE3 · RECRUITING · sponsor: **GC Biopharma Corp** · enrollment: 105 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Undiluted I.V.-Hepabig inj(GC5103)
- **BIOLOGICAL:** Diluted I.V.-Hepabig inj(GC5103)

## Key facts

- **NCT ID:** NCT05686759
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-13
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05686759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05686759, "A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05686759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*